Rosada Rogério S, de la Torre Lucimara Gaziola, Frantz Fabiani G, Trombone Ana P F, Zárate-Bladés Carlos R, Fonseca Denise M, Souza Patrícia R M, Brandão Izaíra T, Masson Ana P, Soares Edson G, Ramos Simone G, Faccioli Lúcia H, Silva Célio L, Santana Maria H A, Coelho-Castelo Arlete A M
Núcleo de Pesquisas em Tuberculose, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo,
BMC Immunol. 2008 Jul 22;9:38. doi: 10.1186/1471-2172-9-38.
The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.
We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 microg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-gamma and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 microg).
Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.
疫苗研发面临的最大挑战包括优化用于人类的DNA疫苗、研发有效的单剂量疫苗、开发不涉及活病毒的递送系统以及鉴定有效的新型佐剂。在此,我们描述了一种高效给小鼠接种抗结核疫苗的新颖、简单技术。我们的技术由与阳离子脂质体复合的单剂量DNA-hsp65基因疫苗制剂组成,并通过鼻内给药。
我们开发了一种新型无毒阳离子脂质体制剂,其中DNA-hsp65疫苗被包裹(ENTR-hsp65)或复合(COMP-hsp65),并通过肌肉内或鼻内途径用于免疫小鼠。尽管两种脂质体制剂均诱导了典型的Th1免疫反应模式,但肌肉内递送途径并未减少杆菌数量。然而,用携带低至25微克质粒DNA的COMP-hsp65进行单次鼻内免疫可显著减少肺部杆菌数量。这些效果伴随着干扰素-γ水平的升高和肺实质的保存,结果类似于用裸DNA-hsp65(共400微克)肌肉内接种四次的小鼠。
我们的目标是克服当前DNA疫苗研发面临的重大障碍。我们在小鼠结核模型中的结果表明,单次鼻内给予COMP-hsp65引发的细胞免疫反应与四次肌肉内给予裸DNA诱导的反应一样强烈。这种制剂使给药的DNA量减少了16倍。此外,我们证明这种疫苗安全、生物相容性好、稳定且易于低成本生产。我们相信这种策略可应用于人类结核单剂量疫苗或初免-加强方案,对控制这种传染病产生巨大影响。